ExploreWatchlistsPricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Total cash & short-term investments

ReproCELL Incorporated (4978)

Market cap
¥16.2B
P/E ratio
-28.2x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal cash & short-term investments (Million JPY)YoY (%)
Mar 31, 20253,942-39.98%
Mar 31, 20246,567+2.94%
Mar 31, 20236,379+37.43%
Mar 31, 20224,642+0.88%
Mar 31, 20214,601-11.27%
Mar 31, 20205,186-9.23%
Mar 31, 20195,713+2.50%
Mar 31, 20185,573+2.96%
Mar 31, 20175,413+0.08%
Mar 31, 20165,409+9.99%
Mar 31, 20154,918

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat